Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Muñoz M, Morales S, Calero JB, Cortesi L, Pintér T, Palácová M, Cherciu N, Petru E, Ettl J, de Almeida C, Villanova G, Raymond R, Minh CTT, Rodrigues A, Cazzaniga ME.
Freyer G, et al. Among authors: rodrigues a.
Breast. 2024 Apr;74:103681. doi: 10.1016/j.breast.2024.103681. Epub 2024 Feb 9.
Breast. 2024.
PMID: 38377732
Free PMC article.
Clinical Trial.